KUALA LUMPUR, Sept 20 -- Solution Group Bhd (SGB) hopes the government would consider including the Convidecia single-dose COVID-19 vaccine as part of the booster dose programme.
Its wholly-owned subsidiary, Solution Biologics Sdn Bhd, is the ASEAN manufacturing partner for CanSino Biologics Inc’s (CanSino) Convidecia vaccine.
In a statement today, SGB said based on a study by Jiangsu Center of Disease Control, a Convidecia booster shot demonstrated an increase of at least 78-fold in average neutralising antibody levels, in comparison with a booster shot with the same inactivated vaccine showing a 15.2-fold increase in antibody levels.
The company added that the study found that taking a booster shot with the vaccine after receiving a two-dose inactivated vaccine was proven to be safe and able to effectively produce an immune response to the COVID-19 virus.
SGB deputy group managing director Datuk Dr Mohd Nazlee Kamal said the company had the infrastructure through its fill and finish facility and the capacity ready to take on the rise in demand.
“We can provide the booster shots for Malaysia and, at the same time, supply to the ASEAN region,” he said.
Malaysia is considering booster shots to enhance the immune system against the virus beginning in early October, while Health Minister Khairy Jamaluddin said earlier today that the details on the booster shot programme would be announced in one or two weeks.
-- BERNAMA
BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 IFLIX channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.
Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial
© 2024 BERNAMA • Disclaimer • Privacy Policy • Security Policy